Vaxcyte Net Working Capital from 2010 to 2024

PCVX Stock  USD 91.70  3.16  3.57%   
Vaxcyte Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vaxcyte Net Working Capital regression line of annual values had r-squared of  0.60 and arithmetic mean of  267,388,920. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
950.6 M
Current Value
998.1 M
Quarterly Volatility
363 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Vaxcyte over the last few years. It is Vaxcyte's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Vaxcyte Net Working Capital Regression Statistics

Arithmetic Mean267,388,920
Geometric Mean126,455,185
Coefficient Of Variation135.76
Mean Deviation283,117,349
Median59,955,000
Standard Deviation363,020,124
Sample Variance131783.6T
Range947.5M
R-Value0.78
Mean Square Error56624.6T
R-Squared0.60
Significance0.0007
Slope62,929,956
Total Sum of Squares1844970.5T

Vaxcyte Net Working Capital History

2024998.1 M
2023950.6 M
2022902 M
2021227.6 M
2020342.1 M
201950.7 M

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital950.6 M998.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.